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ABSTRACT
Objectives Smoking has been connected to
citrullination of antigens and formation of anti-
citrullinated peptide antibodies (ACPAs) in rheumatoid
arthritis (RA). Since smoking can modify proteins by
carbamylation (formation of homocitrulline), this study
was conducted to investigate these effects on vimentin
in animal models and RA.
Methods The efﬁciency of enzymatic carbamylation of
vimentin was characterised. B-cell response was
investigated after immunisation of rabbits with different
vimentin isoforms. Effects of tobacco smoke exposure on
carbamylation of vimentin and formation of
autoantibodies were analysed in mice. The antibody
responses against isoforms of vimentin were
characterised with respect to disease duration and
smoking status of patients with RA.
Results Enzymatic carbamylation of vimentin was
efﬁciently achieved. Subsequent citrullination of vimentin
was not disturbed by homocitrullination. Sera from
rabbits immunised with carbamylated vimentin
(carbVim), in addition to carbVim also recognised human
IgG-Fc showing rheumatoid factor-like reactivity. Smoke-
exposed mice contained detectable amounts of carbVim
and developed a broad immune response against
carbamylated antigens. Although the prevalence of anti-
carbamylated antibodies in smokers and non-smokers
was similar, the titres of carbamylated antibodies were
signiﬁcantly increased in sera of smoking compared with
non-smoking RA. CarbVim antibodies were observed
independently of ACPAs in early phases of disease and
double-positive patients for anti-mutated citrullinated
vimentin (MCV) and anti-carbVim antibodies showed an
extended epitope recognition pattern towards MCV.
Conclusions Carbamylation of vimentin is inducible by
cigarette smoke exposure. The polyclonal immune
response against modiﬁed antigens in patients with RA is
not exclusively citrulline-speciﬁc and carbamylation of
antigens could be involved in the pathogenesis of disease.
Trial registration number ISRCTN36745608;
EudraCT Number: 2006-003146-41.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune
disease in genetically prone individuals where
multiple environmental factors can induce the
inﬂammatory process.1 Interestingly, the speciﬁc
autoimmune response is directed against a number
of different antigens modiﬁed by post-translational
modiﬁcations (PTMs).2 In this context, enzymatic
deimination of peptide-bound arginine to citrulline
by peptidylarginine deiminases (PADs) is consid-
ered as a key mechanism.3 Studies in different
cohorts of RA have revealed that tobacco exposure
increases the risk of anti-citrullinated protein/
peptide antibodies (ACPAs) formation, especially in
carriers of the shared epitope.1 4
Another PTM that has been connected to smoking
is carbamylation of lysine, creating a homologous
citrulline structure that is extended by a single carbon
residual, also known as homocitrulline.5 Various car-
bamylations are formed by the interaction of isocyan-
ate (HNCO) with α-amino and ε-amino groups of
proteins, among them, α-carbamylation, when
α-amino groups of amino acids are involved, and
ε-carbamylation, which is formed by the interaction
of isocyanate with the ε-amino group of lysine.6
In humans, isocyanate is formed by the decom-
position of urea into ammonia and cyanate, which
is transformed to isocyanate. Thus, uraemia second-
ary to renal diseases is a pathological state that
leads to the formation of isocyanate.7
The second key reactant for isocyanate formation
is thiocyanate (SCN−), a metabolite of cyanide that
is present in cigarette smoke. Thiocyanate increases
in urine, serum and saliva with the amount of cigar-
ette smoke.8 Moreover, passive exposure to smoke
signiﬁcantly increased thiocyanate levels when com-
pared with non-exposure.9 Neutrophil myeloperoxi-
dase (MPO) represents a marker of inﬂammation
and is signiﬁcantly higher in smokers than non-
smokers.10 It uses H2O2 to oxidise thiocyanate to
cyanate that subsequently promotes protein carba-
mylation at sites of inﬂammation.11
Mice immunised with carbamylated proteins
(carbP) developed arthritis and a T-cell response
against corresponding antigens. Additionally, anti-
bodies against carbP but not ACPAs were detectable
in mice with collagen-induced arthritis.12 13 It was
also demonstrated that sera from patients with RA
contain different antibody speciﬁcities recognising
either citrulline-containing or homocitrulline-
containing antigens,14 15 and that anti-carbP as well
as ACPAs are detectable even before the onset
of symptoms of RA.16 These ﬁndings suggest that in
addition to citrullination, carbamylation represents
another crucial process in the pathogenesis of RA.17
Accumulating evidence suggests an involvement
of modiﬁed vimentin and anti-modiﬁed vimentin
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antibodies in the pathogenesis of RA.18 19 Vimentin is one of
the most widely expressed mammalian intermediate ﬁlament
proteins. The vimentin network that extends from the nucleus
to the plasma membrane is believed to act as a scaffold, provid-
ing cellular mechanostructural support and thereby maintaining
cell and tissue integrity.20 Therefore, we hypothesised that
vimentin could serve as a substrate for carbamylation from
smoking ingredients and investigated the autoantibody response
against different isoforms of vimentin in patients with RA.
MATERIAL AND METHODS
Modiﬁcation of antigens
Non-enzymatic carbamylation of vimentin was achieved by incu-
bation of vimentin with potassium cyanate (KOCN). Incubation
conditions and quantiﬁcation of carbamylation were performed
as recently described.21 Enzymatic carbamylation was achieved
by incubation of vimentin with MPO (Arotec Diagnostics,
New Zealand), according to the previously described proce-
dures.22 As we described recently,21 incubation of recombinant
vimentin with KOCN achieved approximately 80% carbamylation.
Animals, immunisation and antibodies
Chicken and rabbit antibodies directed against citrullinated
vimentin (citrVim) or carbamylated vimentin (carbVim) were
produced by Davids Biotechnology (Regensburg, Germany).
New Zealand white rabbits were immunised subcutaneously
with 30 mg of peptide emulsiﬁed in adjuvant addavax, an
MF59-like nanoemulsion; the injections were performed every
14 days for ﬁve times. Rabbit polyclonal IgG anti-vimentin anti-
bodies (H-84, Santa Cruz) were employed as reference. To
isolate speciﬁc antibodies, a previously described procedure for
afﬁnity puriﬁcation was used23 (see online supplementary
methods).
Cell fractions as source for modiﬁcation of antigens
To clarify whether a preferential carbamylation of certain pro-
teins occurs, HeLa cell extracts were used for cell fractionation.
Modiﬁed and untreated fractions were used to identify speciﬁ-
city of different sera (see online supplementary methods).
Smoke-exposed mice
For mouse experiments, a whole-body smoking chamber
(Teague TE-10) was used as described.24 Mice (C57BL/6) were
exposed to tobacco smoke for 6 hours over 5 days weekly for
3 weeks. Control mice breathed ﬁltered air.
Serum samples of the respective mice were investigated for
soluble, modiﬁed vimentin by using albumin/immunoglobulin
depletion columns. Subsequently, the throughput was depleted
with trichloroacetic acid (TCA) and separated by 12.5% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Detection of modiﬁed vimentin was performed with an anti-
body speciﬁc for carbVim. After washing of the separation
columns, the eluate from two mice served as controls.
To detect antibodies with different recognition pattern, modi-
ﬁed and untreated HeLa cell fractions together with aliquots of
unmodiﬁed vimentin, citrVim and carbVim were separated by
SDS-PAGE and used for immunoblotting with the indicated sera.
ELISA was used to investigate the concentration of
anti-carbVim in sera of smoking and control mice.
Immunoblotting using sera from patients with RA
Vimentin, citrVim and carbVim were used to detect the
presence of antibodies in sera of patients with RA by
immunoblotting.
Detection of rheumatoid factor IgM and anti- mutated
citrullinated vimentin IgG antibodies by ELISA
Both antibodies were measured using commercially available
ELISA kits (Orgentec Diagnostika, Germany).
Modiﬁcation speciﬁcity of RA autoantibodies and epitope
pattern analysis
The predominant vimentin epitope NH2-GGVYATRSSAVR-OH
was used to synthesise modiﬁed vimentin peptide, citrVim P18
or homocitrulline (carbVim) HC52 (see online supplementary
table S1). Both post-translationally modiﬁed vimentin peptides
were used in ELISA as described,21 25 Carbamylated vimentin
protein was also used in ELISA as described.21 Additionally, the
human full-length vimentin was used to synthesise overlapping
17mer peptides of vimentin resulting in 91 peptides with the
general formula ‘Biotin-SGSG-PEPTIDE-Amide’.23
Patients
Sera from patients with RA fulﬁlling the 2010 American College
of Rheumatology (ACR)/European League Against Rheumatism
criteria (early disease with duration <12 months n=22 and
established disease n=28) in addition to 10 healthy donors
(HDs) were used for immunoblot experiments and for the ana-
lysis of the epitope recognition pattern of patient subgroups
regarding the presence of the different autoantibodies. All estab-
lished patients with RA were treated with conventional disease-
modifying antirheumatic drugs (cDMARDs) and four received
biological DMARDs (three etanercept and one adalimumab) in
combination with cDMARDs. Only two patients with early RA
received cDMARDs. A total of 41 patients (15 with Sjögren’s
syndrome and 26 with systemic lupus erythematosus) in add-
ition to 39 HDs served as control group to calculate sensitivity
and speciﬁcity of vimentin peptides. All samples were obtained
from patients at the Department of Rheumatology and Clinical
Immunology, Charité-Universitätsmedizin, Berlin, Germany,
after approval by the local ethics committee.
For ELISA, all patients were recruited from the double-blind,
randomised controlled trial HIT HARD.26 All patients (n=172)
with recent onset (≤1 year) RA were diagnosed according to the
revised 1987 ACR criteria for the classiﬁcation of RA.
Depending on the smoking status, patients were classiﬁed as
current smokers (n=42), non-smokers (n=68) or ex-smokers
(n=34). At week 24, 118 responders and 12 non-responders
were identiﬁed using the disease activity score 28 erythrocyte
sedimentation rate (DAS28ESR) at baseline and week 24 and
deﬁned as an improvement of ≥1.2.
Statistical analysis
GraphPad Prism (V.4.0) and SPSS (V.19.0) software were used
for statistics. χ2 test was used for association analyses between
smoking and seropositivity of subtype IgG of citrullinated, car-
bamylated and mutated citrullinated vimentin (MCV) anti-
bodies. ORs were calculated. The paired sample sign test was
used to evaluate the differences of antibody titres from baseline
to week 24 and week 48. Mann-Whitney U test was used to
compare antibody titres between different groups. Correlation
analyses were performed using Spearman’s rank correlation test
(rs). p Values <0.05 were considered signiﬁcant.
RESULTS
Kinetics of vimentin modiﬁcation and speciﬁcity
of antibody responses
To test a possible link between inﬂammation and tobacco
smoking, we used the MPO/H2O2/SCN
− system. The amount
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Figure 1 Images showing the rapid citrullination and carbamylation of vimentin under optimal conditions detected by immunoblotting. Induction
of both citrullination and carbamylation generates relevant amounts of antigen after 30 min of exposure. Citrullination can occur after carbamylation
without affecting antigenic properties. (A) Upper lane: Conﬁrmation of carbamylation using a speciﬁc serum. Lower lane: Control with commercial
H-84 antibodies, which shows a reduced signal against vimentin after 10 min and disappearance after 30 min due to complete conversion. (B)
Upper lane: Conﬁrmation of citrullination using a positive anti-citrullinated peptide antibody (ACPA) serum from a patient with rheumatoid arthritis
(RA). Lower lane: Control with commercial H-84 antibodies, which shows reactivities against vimentin as well as against citrullinated isoforms of
vimentin. (C) Upper lane: Conﬁrmation of citrullination after carbamylation using a positive ACPA serum from a patient with RA. Lower lane:
Conﬁrmation of carbamylation using speciﬁc serum. CarbVim, carbamylated vimentin; MCV, mutated citrullinated vimentin; MM, molecular weight
marker.
Figure 2 Representations showing the development of antibody after immunisation of rabbits with carbamylated vimentin (carbVim). (A) Kinetics
of antibody development after immunisation of rabbits with carbVim, vimentin and mutated citrullinated vimentin (MCV). Only immunisations with
carbVim induced the formation of anti-carbVim antibodies. Human IgG-Fc from serum samples of healthy controls was isolated employing
protein-A-afﬁnity chromatography, separated under denatured conditions in SDS-PAGE and transferred onto nitrocellulose membrane for
immunoblotting. IgG heavy chains were recognised by rabbit serum immunised with carbVim. (B) Differences in antibody speciﬁcities (proﬁles) after
immunisation of rabbits with either carbVim (K1-3) or citrullinated vimentin (citrVim) (K4-6). Rabbits were immunised with 20 mg of the indicated
antigen in Freund’s complete adjuvant. Sera from the indicated animals were 1:200 diluted and analysed with the indicated antigens using enzyme
immune assay (observed optical absorption are shown from a representative assay). RF, rheumatoid factor.
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and quality of homocitrullination of MPO-exposed vimentin
was conﬁrmed by immunoblotting using the speciﬁc
anti-carbVim antibodies (anti-carbVim IgY).
As shown in ﬁgure 1A, the anti-carbVim IgY antibodies
were speciﬁc for carbVim and detected the modiﬁed antigen
when the reaction lasted for at least 30 min. Anti-vimentin
antibodies (H-84) veriﬁed the modiﬁcation of lysine residues
by showing a loss of reactivity due to a change of antigenic
epitopes after 30 min of antigen treatment. These results indi-
cate that a peroxidase-supported modiﬁcation system can serve
as an alternative tool for homocitrullination. For comparison,
detection of citrVim is shown in ﬁgure 1B by using anti-
vimentin antibodies and afﬁnity-puriﬁed human ACPAs. This
modiﬁcation is very efﬁcient and the sequential enzymatic
reaction occurs faster than homocitrullination of vimentin in
<10 min.
To monitor if carbamylation antagonises arginine deamination
(citrullination) or vice versa, both reactions were accomplished
sequentially. The respective results are shown in ﬁgure 1C dem-
onstrating that the capacity of PAD to deiminate all arginine
residues of vimentin is not inﬂuenced by the chemical carbamy-
lation, which indicates that in vivo both processes could take
place in parallel or in sequential manner.
Different immunogenicity of vimentin isoforms
Rabbits were immunised with vimentin as well as with the
citrulline-containing and homocitrulline-containing isoforms
and tested for cross-reactivity to carbVim and human IgG-Fc in
immunoblots. Immunisation with carbVim induced antibody
reactivities against both carbVim and human IgG-Fc, showing
rheumatoid factor (RF)-like reactivity. In contrast, rabbits immu-
nised with vimentin or MCV recognised neither carbVim nor
human IgG-Fc (ﬁgure 2A). Using ELISA, rabbits immunised
with citrVim or carbVim were investigated for the presence of
cross-reactivity to vimentin, carbVim, citrVim and human
IgG-Fc. Sera from rabbits immunised with either citrVim or
carbVim showed strong antibody positive bindings speciﬁcally
to their corresponding induced antigens. In addition to the pres-
ence of weak cross-reactivity in both cases, anti-human IgG-Fc
reactivity was only observed in homocitrulline-immunised
rabbits (ﬁgure 2B).
Tobacco exposure to mice induced carbamylation of
antigens and antibody response
Sera of smoking mice contained increased amounts of carbVim
in comparison with control animals (ﬁgure 3A). Smoking mice
also generated antibodies with different speciﬁcities against
Figure 3 Representations showing carbamylated vimentin (carbVim) and antibodies against carbamylated antigens detectable in mouse sera after
smoke exposure. (A) Serum samples derived from mice exposed to smoke contained detectable amounts of carbVim using anti-carb IgY in
immunoblotting. Of note, the observed differences in the SDS-PAGE are well-known phenomena for the different isoforms of vimentin depending on
their degree of citrullination and phosphorylation. (B) Antibodies with different recognition patterns to carbamylated proteins are detectable in sera
of mice exposed to tobacco smoke. Aliquots of unmodiﬁed, citrullinated vimentin or carbVim together with modiﬁed and untreated HeLa cell
fractions (F1 cytosolic proteins, F3 nucleic proteins and F4 components of the cytoskeleton) were subjected to SDS-PAGE (4%–12% NuPAGE,
Invitrogen) for immunoblotting with the indicated sera and anti-vimentin antibodies as a reference. (C) Levels of anti-carbVim antibodies in sera of
smoke exposed and control mice are shown. Mean of titres was shown. Mann-Whitney U test was used and statistical signiﬁcance is indicated for
p<0.05 (*). MCV, mutated citrullinated vimentin.
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carbPs (ﬁgure 3B). Additionally, the concentration of
anti-carbVim antibodies was signiﬁcantly increased in sera of
smoke-exposed mice compared with controls (ﬁgure 3C).
However, during an observation period of 3 weeks, no manifest-
ation of an inﬂammatory joint disease could be observed.
Immunoblotting and epitope recognition patterns of sera
from patients with RA
To clarify whether antibodies against carbVim are detectable in
patients with early RA and whether they form an own class dis-
tinguishable from ACPAs, the respective isoforms were investi-
gated by immunoblotting and ELISA. Immunoblot showed that
patients with RA in all stages of disease expressed reactivities
against either citrVim, carbVim or both isoforms of vimentin
(see online supplementary ﬁgure S1).
To characterise the epitope recognition pattern of patient sub-
groups with respect to the occurrence of the different autoanti-
bodies, overlapping citrullinated peptides resembling the
sequence of vimentin were used. Sera from ACPA and/or
anti-homocitrulline-positive patients in comparison with HDs
(n=10 per group) were investigated using ELISA. An extended
recognition pattern was characteristic for patients with both
antibody subtypes (anti-carbVim and MCV antibodies, see
online supplementary ﬁgure S2C), in comparison with a more
restricted epitope repertoire of sera containing only antibodies
against MCV (see online supplementary ﬁgure S2A). Of note,
patients with positive bindings to carbVim also showed cross-
reactivity with linear citrullinated peptides indicating that their
speciﬁcity to the full length modiﬁed antigen is provided by
conformational epitopes (see online supplementary ﬁgure S2B).
HDs showed negative reactivity (see online supplementary
ﬁgure S2D). All tested sera of patients with RA showed negative
reactivity against unmodiﬁed peptide of vimentin.
IgG antibody patterns of patients with RA (HIT HARD)
against citrullinated (P18) and carbamylated (HC52)
peptides of vimentin using ELISA
Sensitivity, speciﬁcity, positive and negative predictive values of
these antibodies were calculated to evaluate their efﬁciency in
predicting RA development (table 1).
We compared the titre of carbVim antibodies between differ-
ent patient groups with RA classiﬁed according to smoking habit.
The titre of anti-carbVim IgG antibodies was signiﬁcantly higher
in smokers compared with non-smokers. Furthermore, both
Table 1 Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with CI of anti-citrullinated (P18) and
anti-carbamylated (HC52) peptides of vimentin isotype IgG when comparing patients with rheumatoid arthritis (RA) with control group (patients
with Sjögren’s syndrome (n=15), patients with systemic lupus erythematosus (n=26) and healthy donors (n=39))
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Anti-citrVim (P18)
IgG
49.67%
(41.44% to 57.91%)
96.25%
(89.43% to 99.22%)
96.15%
(89.17% to 99.20%)
50.33%
(42.14% to 58.50%)
Anti-carbVim (HC52)
IgG
27.81%
(20.84% to 35.68%)
78.75%
(68.17% to 87.11%)
71.19%
(57.92% to 82.24%)
36.63%
(29.43% to 44.30%)
carbVim, carbamylated vimentin; citrVim, citrullinated vimentin.
Figure 4 Plots showing the autoantibody levels in sera of patients with rheumatoid arthritis (RA) classiﬁed according to the smoking status.
Comparison of autoantibody reactivities of anti-mutated citrullinated vimentin IgG (A MCV IgG), anti-citrullinated peptide of vimentin IgG (A P18
IgG), anti-carbamylated peptide of vimentin IgG (A HC52 IgG) and rheumatoid factor (RF) IgM in sera of patients with early onset RA having known
smoking status. Smokers (n=42), non-smokers (n=68) and ex-smokers (n=34). Cut-off was identiﬁed as 20 U/mL. Values of mean with SEM are
shown. Mann-Whitney U test was used and statistical signiﬁcance is indicated for p<0.05 (*) and p<0.01 (**).
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citrVim and MCV IgG antibodies showed signiﬁcantly increased
titres in smokers compared with non-smokers (ﬁgure 4).
However, analyses of the prevalence of positivity for each
antibody in smokers and non-smokers showed no association
between smoking and the presence of anti-carbVim IgG
(χ2 p=0.229, OR=1.667, 95% CI 0.722 to 3.848). In contrast,
the presence of anti-citrullinated peptide IgG (χ2 p=0.018,
OR=2.571, 95% CI 1.161 to 5.694) and anti-MCV IgG
(χ2 p=0.005, OR=3.096, 95% CI 1.390 to 6.898) was clearly
associated with smoking habit.
Analysis of the coincidence of anti-P18 and anti- HC52 IgG
antibodies with anti-MCV IgG showed that 55.55% of smokers
who showed positivity for anti-MCV IgG were also positive for
anti-carbamylated antibodies (χ2 p=0.0003, OR=38.44, 95%
CI 2.086 to 708.3); this percentage declined to 48% in non-
smokers (χ2 p=0.0008, OR=7.015, 95% CI 2.073 to 23.74)
(see online supplementary table S2).
The prevalence of anticarbamylated IgG antibodies in patients
with RA was lower (28%) compared with anti-MCV IgG,
anti-citrullinated peptide IgG and RF IgM (48.3%, 50% and
46%, respectively). However, the concentration of both
anti-carbamylated and anti-citrullinated peptide IgG antibodies
correlated well with anti-MCV IgG in all patients (rs=0.72,
0.81, respectively, p<0.0001 for both). This effect was stronger
in smokers (rs=0.82, 0.81, respectively, p <0.0001 for both)
compared with non-smokers (rs=0.64, 0.76, respectively,
p<0.0001 for both). Correlation between anti-MCV IgG and
RF IgM in all patients was weak (rs=0.63, p <0.0001) and not
restricted to smoking status.
To clarify whether the titre of anti-citrullinated and
anti-carbamylated IgG antibodies correlates with disease activity
in patients with RA, we classiﬁed the patients into treatment
responders and non-responders according to DAS28ESR. By
comparing the differences from baseline to 24 and 48 weeks
Table 2 The median of differences in titre of anti-mutated citrullinated vimentin IgG (A MCV IgG), anti-citrullinated peptide of vimentin IgG
(A P18 IgG), anti-carbamylated peptide of vimentin IgG (A HC52 IgG) and rheumatoid factor IgM (RF IgM) from baseline to 24 and 48 weeks after
therapy in responder group of patients with rheumatoid arthritis (RA)
DAS28 responses of 118 responders
at week 24 (no. of responders)
Median at
baseline (U/mL)
Median at
week 24 (U/mL)
Median at week
48 (U/mL)
Median of
differences
at week 24
Sign p value
at week 24
Median of
differences
at week 48
Sign p value
at week 48
A MCV IgG
DAS28 ≤2.6
remission (55/118)
15.210 13.628 14.150 −2.129 0.002** −3.050 0.000***
DAS28 ≤ 3.2 and >2.6
low disease activity (15/118)
41.500 21.600 69.500 −14.452 0.022* −4.100 0.581
DAS28 ≤ 5.1 and >3.2
moderate disease activity (44/118)
32.378 19.810 20.864 −5.676 0.000*** −4.874 0.009**
DAS28 >5.1
high disease activity (4/118)
73.474 112.860 11.444 53.541 0.625 −18.203 1.000
A P18 IgG
DAS28 ≤2.6
remission (55/118)
12.950 12.450 15.300 −1.100 0.007** −1.250 0.012*
DAS28 ≤ 3.2 and > 2.6
low disease activity (15/118)
125.000 32.600 95.200 −0.400 0.581 1.400 1.000
DAS28 ≤ 5.1 and > 3.2
moderate disease activity (44/118)
44.100 35.800 21.500 −1.950 0.035* −0.900 0.045*
DAS28 >5.1
high disease activity (4/118)
48.900 65.700 4.500 −4.850 1.000 −7.500 1.000
A HC52 IgG
DAS28 ≤2.6
remission (55/118)
11.550 9.850 8.500 −0.950 0.034* −0.600 0.203
DAS28 ≤ 3.2 and >2.6
low disease activity (15/118)
14.900 8.200 9.700 −1.500 0.039* −1.200 0.388
DAS28 ≤ 5.1 and >3.2
moderate disease activity (44/118)
9.000 8.850 6.900 −0.700 0.100 −0.850 0.090
DAS28 > 5.1
high disease activity (4/118)
8.350 22.350 4.200 −2.100 1.000 −1.000 1.000
RF IgM
DAS28 ≤ 2.6
remission (55/118)
10.613 7.500 8.900 −2.525 0.000*** −1.365 0.012*
DAS28 ≤ 3.2 and > 2.6
low disease activity (15/118)
28.399 13.000 17.800 −2.600 0.022* −3.400 0.022*
DAS28 ≤ 5.1 and > 3.2
moderate disease activity (44/118)
18.400 6.411 9.355 −9.990 0.000*** −4.058 0.000***
DAS28 >5.1
high disease activity (4/118)
167.550 161.650 61.000 141.600 0.625 34.500 1.000
The analysis was done in relation to their achieved DAS28 response after 24 weeks of treatment. Paired sample sign test was used and statistical significance is indicated for p<0.05 (*),
p<0.01 (**) and p<0.001 (***).
DAS28, disease activity score 28.
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after therapy in both groups, the titre reduction did not reﬂect
improved treatment response for all tested antibodies (table 2).
However, at 24 and 48 weeks, a signiﬁcant titre reduction of
anti-MCV IgG, RF IgM and to a lesser extent of anti-citrulli-
nated and anti-carbamylated antibodies was observed in respon-
ders with the exception of those with constant high disease
activity. Due to low numbers of non-responders, no statistical
evaluation was possible.
Notably, the therapeutic effect for induction of response and
remission was affected by smoking habit; thus, whereas almost
55% of non-smokers achieved remission, only 40% of smokers
and 36% of ex-smokers reached the same outcome.
DISCUSSION
Smoking has been identiﬁed as a major risk factor for the induc-
tion and perpetuation of RA.27 The current pathogenetic model
suggests citrullination of antigens in the lungs and elsewhere as
a driving process.28 However, it seems that the signiﬁcance of
other PTMs such as carbamylation has not been recognised suf-
ﬁciently so far.
In this study, we characterised the extent and the kinetics of
carbamylation of vimentin as a well-known autoantigen with
close association to the pathogenesis of RA. We provided clear
evidence that carbVim and not citrVim is a strong antigen that
induces a B-cell response against itself and against human
IgG-Fc in an animal model, thus inducing a RF-like activity.
Almost the whole spectrum of autoantibodies characteristic of
RA was induced. Moreover, in agreement with other
studies,29 30 we showed that the autoimmune response against
carbVim is an early event in the pathogenesis of RA.
Additionally, we proved that vimentin, as a major and well-
characterised autoantigen in RA, does form its own class of car-
bamylated antigens that could be strongly recognised by antisera
induced only with the corresponding antigen in an animal
model. The cross-reactions, which have been seen in
carbVim-positive RA sera as well as in antisera of rabbits immu-
nised with carbVim, could occur in ureido group-speciﬁc
manner. Furthermore, we showed that both carbamylation and
citrullination are independent processes that may happen in par-
allel or in sequential manner.
In a mouse model, we showed that carbamylation of vimentin
can be triggered by exposure to tobacco smoke and that this
antigen and potentially other modiﬁed proteins are able to
induce a broad immune reaction against many variants of carbP.
Additionally, a signiﬁcantly increased level of anti-carbamylated
antibodies was observed in smoke-exposed mice and smoking
patients with RA when compared with ﬁltered air-exposed or
non-smoking controls. However, in agreement with other
studies,25 29 no association between smoking and
anti-carbamylated antibody positivity was detected in patients
with RA. These ﬁndings support the idea that carbamylation in
smokers and non-smokers could be induced by additional trig-
gering factors including even passive exposure to tobacco
smoke. Nevertheless, smoking induced increased titres of carba-
mylated antibodies in humans and mouse models.
In our previous study on Cuban patients,21 the prevalence of
IgG antibodies against carbamylated peptides of vimentin was
higher (60% and almost 80% in early and established RA,
respectively) than in the present study (28%). It has been shown
that the combination of major histocompatibility complex, class
II, DR beta 1 (HLA-DRB1)-shared epitope alleles and smoking
is associated with RA susceptibility31 and different genetic asso-
ciations of autoantibody-positive disease subgroups was identi-
ﬁed in relation to the presence of DRB1*04.32 These ﬁndings
suggest that the discrepancy in the frequencies of autoantibodies
between different populations could be attributed to the genetic
heterogeneity, as well as different environmental and behav-
ioural factors.
Notably, the epitope recognition patterns and the coincidences
of anti-carbamylated with anti-MCV antibodies suggest a strong
association between these antibodies in RA. This is in agreement
with a recently described association of anti-carbP and anti-
citrVim that could not be explained by cross-reactivity.33
Of note, a treatment-related reduction of antibody titres was
less obvious for anti-carbamylated antibodies compared with all
other tested antibodies. This indicates that anti-carbamylated
antibodies are produced by a distinct B-cell subset, which
appears to be more treatment-resistant.
In conclusion, we demonstrated that the polyclonal immune
response against modiﬁed antigens in RA is restricted to citrulli-
nated and carbamylated autoantigens, which could be involved
in the pathogenesis of disease and response to therapy. Direct or
indirect exposure to tobacco smoke could have an effect by
inducing carbamylation, which could trigger a pathogenic B-cell
response.
Acknowledgements The authors thank Tanja Braun for her support in clinical
data collection in the randomised controlled trial (RCT) HIT HARD and Annushka
Wurdinger for assistance in immunoblotting.
Contributors CO performed the analysis of the mouse experiments and
contributed in writing and reviewing the manuscript; HB advised vimentin
carbamylation, animal immunisation, HeLa cell fractionation, Western blot analysis,
ELISA kits developing and contributed in writing and reviewing the manuscript; EF
designed the study, collected the results and contributed in writing and reviewing
the manuscript; GC and SK performed and designed the analysis of the mouse
experiments and contributed in reviewing the manuscript; JD collected samples and
clinical data of RCT HIT HARD and contributed in reviewing the manuscript; AK
developed and performed the analysis of the ELISA kits, immunoblot experiments
and contributed in reviewing the manuscript; SG contributed to the study design
and in reviewing the manuscript; KG performed and designed the analysis of ELISA
experiments, collected clinical data and contributed in writing and reviewing the
manuscript and GRB contributed to the study design and in writing and reviewing
the manuscript.
Funding The study was supported by the FP7 HEALTH programme under the grant
agreement FP7-HEALTHF2-2012-305549, HIT HARD study (German Federal Ministry
of Education and Research (BMBF, grant number: 01KG0602) and EU IMI grant
BeTheCure, contract no 115142-2; ArthroMark of the German Federal Ministry of
Education and Research (BMBF, grant number: 01EC1401A).
Competing interests HB is an employee of Orgentec Diagnostika GmbH, Mainz,
Germany; test kits were kindly provided by Orgentec.
Patient consent Obtained.
Ethics approval Charité-Universitätsmedizin Berlin, Germany.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Hensvold AH, Magnusson PK, Joshua V, et al. Environmental and genetic factors in
the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive
rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis
2015;74:375–80.
2 Bax M, Huizinga TW, Toes RE. The pathogenic potential of autoreactive antibodies
in rheumatoid arthritis. Semin Immunopathol 2014;36:313–25.
3 van Venrooij WJ, Pruijn GJ. How citrullination invaded rheumatoid arthritis research.
Arthritis Res Ther 2014;16:103.
4 Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental
determinants for disease risk in subsets of rheumatoid arthritis deﬁned by the
anticitrullinated protein/peptide antibody ﬁne speciﬁcity proﬁle. Ann Rheum Dis
2013;72:652–8.
Ospelt C, et al. Ann Rheum Dis 2017;0:1–8. doi:10.1136/annrheumdis-2016-210059 7
Clinical and epidemiological research
5 Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links
inﬂammation, smoking, uremia and atherogenesis. Nat Med
2007;13:1176–84.
6 Jaisson S, Pietrement C, Gillery P. Carbamylation-derived products: bioactive
compounds and potential biomarkers in chronic renal failure and atherosclerosis.
Clin Chem 2011;57:1499–505.
7 Kraus LM, Kraus AP Jr. Carbamylation of amino acids and proteins in uremia.
Kidney Int Suppl 2001;78:S102–7.
8 Zil-a-Rubab, Rahman MA. Serum thiocyanate levels in smokers, passive smokers
and never smokers. J Pak Med Assoc 2006;56:323–6.
9 Husgafvel-Pursiainen K, Sorsa M, Engström K, et al. Passive smoking at work:
biochemical and biological measures of exposure to environmental tobacco smoke.
Int Arch Occup Environ Health 1987;59:337–45.
10 Andelid K, Bake B, Rak S, et al. Myeloperoxidase as a marker of increasing systemic
inﬂammation in smokers without severe airway symptoms. Respir Med
2007;101:888–95.
11 van Dalen CJ, Whitehouse MW, Winterbourn CC, et al. Thiocyanate and
chloride as competing substrates for myeloperoxidase. Biochem J 1997;327
(Pt 2):487–92.
12 Stoop JN, Liu BS, Shi J, et al. Antibodies speciﬁc for carbamylated proteins precede
the onset of clinical symptoms in mice with collagen induced arthritis. PLoS ONE
2014;9:e102163.
13 Mydel P, Wang Z, Brisslert M, et al. Carbamylation-dependent activation of T cells:
a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol
2010;184:6882–90.
14 Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated
proteins are present in sera of patients with rheumatoid arthritis and predict joint
damage. Proc Natl Acad Sci USA 2011;108:17372–7.
15 Scinocca M, Bell DA, Racape M, et al. Antihomocitrullinated ﬁbrinogen antibodies
are speciﬁc to rheumatoid arthritis and frequently bind citrullinated proteins/
peptides. J Rheumatol 2014;41:270–9.
16 Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP)
antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis
2014;73:780–3.
17 Shi J, van Veelen PA, Mahler M, et al. Carbamylation and antibodies against
carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev
2014;13:225–30.
18 Turesson C, Mathsson L, Jacobsson LT, et al. Antibodies to modiﬁed citrullinated
vimentin are associated with severe extra-articular manifestations in rheumatoid
arthritis. Ann Rheum Dis 2013;72:2047–8.
19 Sokolove J, Brennan MJ, Sharpe O, et al. Brief report: citrullination within the
atherosclerotic plaque: a potential target for the anti-citrullinated protein
antibody response in rheumatoid arthritis. Arthritis Rheum
2013;65:1719–24.
20 Lundkvist A, Reichenbach A, Betsholtz C, et al. Under stress, the absence of
intermediate ﬁlaments from Muller cells in the retina has structural and functional
consequences. J Cell Sci 2004;117(Pt 16):3481–8.
21 Martinez G, Gómez JA, Bang H, et al. Carbamylated vimentin represents a relevant
autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatol Int
2016;36:781–91. .
22 Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic
pathway for atherosclerotic vascular disease. Clin Sci 2009;116:681–95.
23 Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss
by human autoantibodies against citrullinated vimentin. J Clin Invest
2012;122:1791–802.
24 Ospelt C, Camici GG, Engler A, et al. Smoking induces transcription of the heat
shock protein system in the joints. Ann Rheum Dis 2014;73:1423–6.
25 Juarez M, Bang H, Hammar F, et al. Identiﬁcation of novel antiacetylated vimentin
antibodies in patients with early inﬂammatory arthritis. Ann Rheum Dis
2016;75:1099–107.
26 Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus
methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48
versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid
arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis
2013;72:844–50.
27 Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for
rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.
Ann Rheum Dis 2011;70:508–11.
28 Lugli EB, Correia RE, Fischer R, et al. Expression of citrulline and homocitrulline
residues in the lungs of non-smokers and smokers: implications for autoimmunity in
rheumatoid arthritis. Arthritis Res Ther 2015;17:9.
29 Brink M, Verheul MK, Ronnelid J, et al. Anti-carbamylated protein antibodies in the
pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple
anti-citrulline peptide antibodies and association with radiological damage. Arthritis
Res Ther 2015;17:25.
30 Shi J, van Steenbergen HW, van Nies JA, et al. The speciﬁcity of anti-carbamylated
protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res
Ther 2015;17:339.
31 Bang SY, Lee KH, Cho SK, et al. Smoking increases rheumatoid arthritis
susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of
rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum
2010;62:369–77.
32 Snir O, Gomez-Cabrero D, Montes A, et al. Non-HLA genes PTPN22, CDK6 and
PADI4 are associated with speciﬁc autoantibodies in HLA-deﬁned subgroups of
rheumatoid arthritis. Arthritis Res Ther 2014;16:414.
33 Challener GJ, Jones JD, Pelzek AJ, et al. Anti-carbamylated Protein Antibody Levels
Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid
Arthritis. J Rheumatol 2016;43:273–81.
8 Ospelt C, et al. Ann Rheum Dis 2017;0:1–8. doi:10.1136/annrheumdis-2016-210059
Clinical and epidemiological research
